HealthCap IX, the latest fund from Swedish venture firm HealthCap, has secured €48 million in a joint investment from Novo Holdings and the Export and Investment Fund of Denmark (EIFO). With this boost, HealthCap will deepen its presence in the Nordics by opening a hub at Copenhagen’s BioInnovation Institute (BII), aimed at nurturing early-stage biotech ventures born from academic and corporate research. A veteran in precision medicine and breakthrough therapeutics, HealthCap has backed over 130 companies and contributed to the development of more than 30 approved drugs. The fund will use the new capital to advance companies addressing critical unmet medical needs, aligning closely with Novo Holdings’ seed investment strategy. This marks EIFO’s first partnership with HealthCap, underscoring Denmark’s ambition to anchor global life science leadership through strategic funding and regional collaboration.
HealthCap is a longstanding and recognised venture firm with a strong presence in the Nordics. Since its founding in 1996, it has built a strong track record of supporting companies that address serious medical conditions through novel therapeutic approaches. With investments in more than 130 companies, HealthCap has played a central role in developing over 30 approved pharmaceutical products and more than 50 innovative medical technologies – benefitting millions of patients globally.
HealthCap’s focus is on precision medicine and therapies targeting areas of high unmet medical need, which aligns closely with the strategy of Novo Holdings’ Seed Investments vertical. The Seed Investments team at Novo Holdings backs early-stage biotech companies emerging from strong science, often at the point of spinout from academic institutions. HealthCap’s expertise in identifying and supporting such companies through their growth journey makes the fund a natural partner.
This marks EIFO’s first investment with HealthCap, while Novo Holdings has previously backed earlier HealthCap funds.
Mårten Steen, Managing Partner, HealthCap, said:
“We are proud to welcome two of Denmark’s most respected investors as LPs in HealthCap IX. The investments from Novo Holdings and EIFO not only enhance HealthCap’s ability to support transformative healthcare companies but also reinforce the Nordic region’s position as a global leader in life science innovation and entrepreneurship.”
Daniel Rasmussen, Principal, Seed Investments, Novo Holdings, said:
“We are pleased to continue our collaboration with HealthCap, which over many years has proven to be a strong partner in advancing the next generation of healthcare solutions. With this commitment, we aim to support high-quality scientific projects in the Nordics and ensure they have the support needed to develop into well-structured companies with clinical and commercial success.”
Rikke Michaela Greve, Investment Manager, EIFO, added:
“With its strong track record, good reputation, and well-established network in Denmark, HealthCap is a key player and a local anchor for Danish life sciences. It has the ability to attract international investment and collaboration, which is vital to securing sufficient funding for the region.”
Click here to read more VC news.
Read the orginal article: https://arcticstartup.com/novo-holdings-and-eifo-invest-e48m-in-healthcap-ix/
